AFFILIATIONS
1 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 University of Washington, Seattle, Washington, United States
5 University of Washington, Seattle, Washington, United States
6 University of Washington, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Introduction
An estimated 10-20% of patients with immune thrombocytopenia (ITP) develop chronic, difficult-to-treat disease characterized by poor responses, toxicities associated with recurrent rescue therapies (e.g. IVIG, corticosteroids), and/or intolerance to early line agents like TPO-RA or rituximab. To better understand treatment patterns with next-line therapies, we retrospectively evaluated the real-world safety and efficacy of rilzabrutinib(rilza), fostamatinib(fosta), daratumumab(dara), and mycophenolate mofetil(MMF), used alone or with TPO-RA, rituximab, IVIG, or low-dose steroids(<20 mg/day) in patients with chronic ITP.
Methods
We conducted a single-center retrospective study of adults with chronic ITP treated at UW/Fred Hutch from 2019-2026.Patients were identified by ITP diagnostic codes, confirmed to have chronic ITP by two hematologists, and included if they received rilza, fosta, dara, or MMF alone or with other ITP therapies. Each of the four therapeutic agents were analyzed as a separate exposure; individual patients could contribute more than once if treated with more than one agent. Initial response was defined as a platelet count ≥30x109/L and at least ≥2-fold increase from baseline, not attributable to rescue therapies. Sustained response was defined as maintenance of platelet counts ≥30x109/L for at least 3 months without rescue therapy among patients remaining on treatment for at least 3 months after initial response. We also evaluated median time to initial response and adverse events(AEs) including those causing treatment discontinuation. Outcomes were summarized descriptively for each cohort.
Results
Among 1,679 patients identified using ITP diagnostic codes, dual hematologist review confirmed the diagnosis of chronic ITP and identified 96 qualifying treatment exposures: rilza[n=16], fosta[n=33], dara[n=10], and MMF[n=37]. Median age at treatment initiation was 62[range, 38-82], 51[20-82], 55[27-82], and 49[19-82] years, respectively. Median time from ITP diagnosis to treatment initiation was 3.7[0-16], 0.9[0-17], 5.7[0.4-23], and 2.0[0-63] years, respectively. Patients received a median of 5[2-11], 7[0-9], 8[2-11], and 5[0-9] prior ITP-directed therapies, respectively. Previous splenectomy was noted in 7/16[44%], 11/33[33%], 4/10[40%], and 7/37[19%] of patients, respectively.
Platelet responses occurred in 8/16[50%] with rilza,14/33[42%] with fosta,4/10[40%] with dara, and 23/37[59%] with MMF. Median time to first response was 19[1-44], 51[2-143], 6[2-17], and 24[2-337] days, respectively. Among responders treated for at least 3 months, sustained responses occurred in 6/8[75%], 10/14[71%], 2/2[100%], and 20/23[87%], respectively. Among patients who discontinued therapy, treatment-related AEs were the primary reason in 3/8[38%] with rilza, 11/25[44%] with fosta, 0/10[0%] with dara, and 4/18[22%] with MMF. Common AEs included nausea, vomiting, and diarrhea with rilza; transaminitis, neutropenia, diarrhea, and hypertension with fosta; and nausea and heartburn with MMF. Mild infusion reactions were noted in 2/10[20%] of patients on dara but did not lead to treatment discontinuation. Few patients, 1/6[17%] on rilza, 2/10[20%] on fosta, 0/2[0%] on dara, and 0/20[0%] on MMF, achieved sustained response on monotherapy. Responders were on a median of 2[0-4], 1[0-4], 3[1-4], 2[1-4] concomitant therapies with each of these agents, respectively.
Conclusions
In this heavily pretreated cohort, meaningful platelet responses were observed with all four agents evaluated. We hypothesize the higher observed response with MMF may be attributable to institutional practice favoring its earlier use compared to the other agents. Dara followed by rilza had the shortest observed time to response. Dara also demonstrated the highest observed sustained response rates, though this estimate was based on only two evaluable responders. Fosta showed the lowest observed rate of sustained response and the highest proportion of AE related discontinuations. Few patients in our cohort achieved sustained response with monotherapy using these agents. While this study is the first to examine the contemporaneous use of recently approved or off-label agents in chronic ITP, small sample sizes, institution specific practices, retrospective data, and variable use of mono- versus combination therapy preclude direct comparisons across agents. Larger prospective studies are urgently needed to guide use of later-line therapies for chronic ITP.
DISCLOSURES
Ganesh Raman, MD: No relevant conflicts of interest to declare.